When was Nanobots Therapeutics founded?

Nanobots Therapeutics was founded in 2023 and raised its 1st funding round within a year of its incorporation.

Where is Nanobots Therapeutics located?

Nanobots Therapeutics is headquartered in Barcelona, Spain.

How many employees does Nanobots Therapeutics have?

As of Jul 31, 2026, the latest employee count at Nanobots Therapeutics is 15.

Is Nanobots Therapeutics a funded company?

Nanobots Therapeutics is a funded company, having raised a total of $1.57M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Sep 22, 2023.

When was the latest funding round of Nanobots Therapeutics?

Nanobots Therapeutics' latest funding was a $***** Seed round on Dec 02, 2024, with participation from 0 investor.

Where does Nanobots Therapeutics rank among its competitors?

Nanobots Therapeutics ranks 1352nd amongst 3303 active competitors, of which 1117 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Nanobots Therapeutics?

Nanobots Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Nanobots Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of therapeutics for the treatment of cancer. It offers a lead candidate NBT-101 for bladder cancer, NBT-102 for colorectal cancer, and others. It offers a proprietary MotionTx technology platform to develop therapeutic candidates that cano cross biological barriers and accumulate in target cells.

Website: www.nanobotstx.com/
Phone Number: +34 **********

Key Metrics

Founded Year

2023

Location

Barcelona, Spain

Stage

Seed

Total Funding

$1.57M in 2 rounds

Latest Funding Round

Seed, Dec 02, 2024, $*****

Investors

Banco Sabadell & 3 more

Ranked

1352^nd among 3303 active competitors

Employee Count

15 as on Jul 31, 2026

Similar Companies

Jazz Pharmaceuticals & 2984 more

View Nanobots Therapeutics' full profile

Nanobots Therapeutics has raised a total funding of $1.57M over 2 rounds. Its first funding round was on Sep 22, 2023. Nanobots Therapeutics has 4 institutional investors.

Here is the list of recent funding rounds of Nanobots Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 02, 2024	2352940	Seed	4498921	1165435	1846492	4869668
Sep 22, 2023	8467390	Seed	3822836	4002625	Banco Sabadell	Prous Institute for Biomedical Research & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Nanobots Therapeutics's funding rounds and investors

The founders of Nanobots Therapeutics are Gonzalo Fernandez Miranda, Isaac Cabezas Banos, Andres G Fernandez and Daniel Oliver.

Here are the details of Nanobots Therapeutics' key team members:

Gonzalo Fernandez Miranda: Co-Founder of Nanobots Therapeutics.
Isaac Cabezas Banos: Co-Founder of Nanobots Therapeutics.
Andres G Fernandez: Co-Founder of Nanobots Therapeutics.
Daniel Oliver: Co-Founder of Nanobots Therapeutics.

View details of Nanobots Therapeutics's Founder profiles and Board Members

Nanobots Therapeutics' employee count trend

Nanobots Therapeutics has 15 employees as of Jul 26. Here is Nanobots Therapeutics's employee count trend over the years:

Employee count trend for Nanobots Therapeutics

Uncover Nanobots Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Nanobots Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Nanobots Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 18 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
1352nd	Nanobots Therapeutics 2023, Barcelona (Spain), Seed	Developer of therapeutics for the treatment of cancer	$1.57M	Banco Sabadell, Esade Alumni & 2 others	36/100